Patient-level outcomes and virologic suppression rates in HIV-infected patients receiving antiretroviral therapy in Rwanda

Abstract

The Rwanda national HIV program has been successful at scaling up antiretroviral therapy (ART) to achieve universal access. The AIDSRelief Model of Care focuses on four key principles: (1) earlier initiation of ART; (2) use of durable, highly-potent, and sequence-friendly first-line ART regimens; (3) early detection of treatment failure; and (4) provision of community-based care and support to ensure optimal adherence and follow up/engagement in care. We conducted a retrospective cohort study of randomly-selected HIV-infected patients at AIDSRelief-supported sites using a stratified, random sample of 583 adults (>15 years) who initiated ART from 30 June 2008 to 1 February 2010. At ART initiation, the median patient age was 38 years, and 67% were female. The baseline median CD4+ cell count was 309 cells/mm³. Overall virologic suppression was 91%. Married/ever married status (adjusted prevalence odds ratio [aPOR] 3.75, 95% confidence interval [CI] 1.30–10.78) and self-reported adherence ≥95% in the past month (aPOR 2.76, 95% CI 1.00–7.62) were significantly associated with viral suppression in the multivariable model. Excellent virologic outcomes were achieved in Rwandan AIDSRelief sites utilizing the AIDSRelief Model of Care during the scale-up of ART in the country.

Keywords

HIV Rwanda AIDSRelief virologic outcomes,antiretroviral therapy

Get full access to this article

View all access options for this article.

References

World Health Organization. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector – progress report, http://www.who.int/hiv/pub/tuapr_2009_en.pdf (2007, accessed 20 July 2009).

World Health Organization, UNAIDS and UNICEF. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector, progress report 2010, http://www.who.int/hiv/pub/2010progressreport/full_report_en.pdf (2010, accessed 19 November 2010).

Nsanzimana

Ruton

Lowrance

et al . Cell phone-based and internet-based monitoring and evaluation of the National Antiretroviral Treatment Program during rapid scale-up in Rwanda: TRACnet, 2004. Acquir Immune Defic Syndr 2012; 59: e17.

Nsanzimana

Kanters

Remera

et al . HIV care continuum in Rwanda: A cross-sectional analysis of the national programme. Lancet HIV 2015; 2: e208–e215.

Rich

Miller

Niyigena

et al . Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. J Acquir Immune Defic Syndr 2012; 59: e35–e42.

Elul

Basinga

Nuwagaba-Biribonwoha

et al . High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS One 2013; 8: e53586.

Rusine

Asiimwe-Kateera

van de Wijgert

et al . Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. PLoS One 2013; 8: e64345.

Nsanzimana

Remera

Kanters

et al . Life expectancy among HIV-positive patients in Rwanda: A retrospective observational cohort study. Lancet Glob Health 2015; 3: e169–e177.

Bendavid

Stauffer

Remera

et al . Mortality along the continuum of HIV care in Rwanda: a model-based analysis. BMC Infect Dis 2016; 16: 728

10.

Wandeler

Johnson

LF and

Egger

Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS 2016; 11: 492–500.

11.

Shubber

Mills

Nachega

et al . Patient-reported barriers to adherence to antiretroviral therapy: A systematic review and meta-analysis. PLoS Med 2016; 13: e1002183.

12.

Croome

Ahluwalia

Hughes

et al . Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa. AIDS 2017; 31: 995–1007.

13.

Etienne

Burrows

Osotimehin

et al . Situational analysis of varying models of adherence support and loss to follow up rates: Findings from 27 treatment facilities in eight resource limited countries. Trop Med Int Health 2010; 15: 76–81.

14.

Etienne

Hossain

Redfield

et al . Indicators of adherence to antiretroviral therapy treatment among HIV/AIDS patients in 5 African countries. J Int Assoc Physicians AIDS Care 2010; 9: 98–103.

15.

Handford

Rackal

Tynan

et al . The association of hospital, clinic and provider volume with HIV/AIDS care and mortality: Systematic review and meta-analysis. AIDS Care 2012; 24: 267–282.

16.

Barth

van der Loeff

Schuurman

et al . Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: A systematic review. Lancet Infect Dis 2010; 10: 155–166.

17.

Boender

Sigaloff

McMahon

et al . Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: A systematic review and meta-analysis. Clin Infect Dis 2015; 61: 1453–1461.

18.

Fatti

Mothibi

Shaikh

et al . Improved long-term antiretroviral treatment outcomes amongst patients receiving community-based adherence support in South Africa. AIDS Care 2016; 28: 1365–1372.

19.

Binagwaho

Kankindi

Kayirangwa

et al . Transitioning to country ownership of HIV programs in Rwanda. PLoS Med 2016; 13: e1002075.